Rx For Industry: Key Provisions Of The 21st Century Cures Act
Executive Summary
Changes to the priority review voucher program, economic communications with payors, and approval of antimicrobial products all have the potential to impact the commercial prospects of drugmakers.
You may also be interested in...
Antibiotic Development: Limited Population Pathway In US Removes Barrier
Allergan's Avycaz could be indicator of how FDA will use the 21st Century Cure's new approval mechanism; experts maintain the provision does not lower FDA's standards of safety.
Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices
Executive order mandating two existing regulations be eliminated for every new one issued includes guidances, raising questions about how FDA will communicate with industry going forward.
Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing
CEO pledges transparency and responsible pricing of J&J drugs during the company’s earnings call, while outlining its goals for US health care and tax reform. Fourth quarter performance was unspectacular, although J&J's oncology and immunology portfolios showed sales growth.